XOMA Royalty Acquires LAVA Therapeutics N.V.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

AbbVie Acquires Landos Biopharma

May 23, 2024

Biotechnology

AbbVie has completed the acquisition of clinical-stage biopharmaceutical company Landos Biopharma, adding Landos’ lead investigational asset NX-13 — an oral NLRX1 agonist in Phase 2 for ulcerative colitis — to AbbVie’s immunology pipeline. The deal was valued at $20.42 per share plus contingent value rights tied to a clinical milestone and will take Landos private, with Landos common stock ceasing NASDAQ trading prior to May 24, 2024.

Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M

November 4, 2024

Biotechnology

Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).

Innoviva Acquires La Jolla Pharmaceutical Company

July 11, 2022

Pharmaceuticals

Innoviva, Inc. completed a cash tender offer to acquire La Jolla Pharmaceutical Company for $6.23 per share, valuing the deal at an implied enterprise value of approximately $149 million. The acquisition adds La Jolla's marketed infectious disease and hospital products (GIAPREZA and XERAVA) to Innoviva's healthcare portfolio to expand its commercial footprint in anti-infectives and hospital therapeutics.

Charles River Laboratories Acquires Explora BioLabs

April 6, 2022

Biotechnology

Charles River Laboratories has acquired Explora BioLabs Holdings, a San Diego–based provider of contract vivarium services, for approximately $295 million in cash. The deal expands Charles River’s CRADL footprint with more than 15 additional vivarium facilities (bringing expected combined capacity to at least 25 sites and ~300,000 sq ft by end of 2022) and adds complementary preclinical vivarium management capabilities and clients.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.